
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Dalton Pharma completes its $2.5 million expansion in Toronto for sterile and aseptic filling capabilities.
Dalton Pharma Services
, a privately owned pharmaceutical services provider, reported the completion of a $2.5 million expansion of its sterile and aseptic filling capabilities in Toronto, Canada. This project included addition ofsterile vial processing and washing, expanded vial depyrogenation capability, automated vial inspection capability, a new Water For Injection (WFI) system, and expanded and improved gowning areas for GMP manufacturing operators.
Source:
Dalton Pharma Services






